Evidence map›Paper›PMID 41055887›Full record

ArticleChembiochem : a European journal of chemical biology2025

Functionalizing Injectable Hydrogels with Cobalt-Based Metallacarboranes for Targeted Delivery in Triple-Negative Breast Cancer.

Neville Murphy, Roberto González-Gómez, Nivethitha Ashok, Enda O'Connell, Howard Fearnhead, William J Tipping, Karen Faulds, Wenming Tong, Abhay Pandit, Róisín M Dwyer and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Neville MurphySchool of Biological and Chemical Sciences, Ryan Institute, University of Galway, H91 CF50, Galway, Ireland.ORCID https://orcid.org/0000-0002-1654-8383
Roberto González-GómezSchool of Biological and Chemical Sciences, Ryan Institute, University of Galway, H91 CF50, Galway, Ireland.ORCID https://orcid.org/0000-0003-4200-2541
Nivethitha AshokSchool of Biological and Chemical Sciences, Ryan Institute, University of Galway, H91 CF50, Galway, Ireland.
Enda O'ConnellGenomics and Screening Core, University of Galway, H91 W2TY, Galway, Ireland.ORCID https://orcid.org/0000-0001-7441-0262
Howard FearnheadPharmacology and Therapeutics, University of Galway, H91 TK33, Galway, Ireland.ORCID https://orcid.org/0000-0002-8054-9794
William J TippingCentre for Molecular Nanometrology, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, Glasgow, G1 1RD, UK.ORCID https://orcid.org/0000-0003-4273-2691
Karen FauldsCentre for Molecular Nanometrology, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, Glasgow, G1 1RD, UK.ORCID https://orcid.org/0000-0002-5567-7399
Wenming TongSchool of Biological and Chemical Sciences, Ryan Institute, University of Galway, H91 CF50, Galway, Ireland.ORCID https://orcid.org/0000-0002-4831-4960
Abhay PanditCÚRAM Research Ireland Centre for Medical Devices, University of Galway, H91 W2TY, Galway, Ireland.ORCID https://orcid.org/0000-0002-6292-4933
Róisín M DwyerCÚRAM Research Ireland Centre for Medical Devices, University of Galway, H91 W2TY, Galway, Ireland.ORCID https://orcid.org/0000-0002-5854-0339
Duncan GrahamCentre for Molecular Nanometrology, Department of Pure and Applied Chemistry, Technology and Innovation Centre, University of Strathclyde, Glasgow, G1 1RD, UK.ORCID https://orcid.org/0000-0002-6079-2105
Pau FarràsSchool of Biological and Chemical Sciences, Ryan Institute, University of Galway, H91 CF50, Galway, Ireland.ORCID https://orcid.org/0000-0003-3859-2868

Funding

Engineering and Physical Sciences Research Council EP/N010914/1National Breast Cancer Research Institute FY24001Research Ireland 13/RC/2073 P2
6 · The paper itself

Abstract

Cobalt-based metallacarboranes have emerged as potential candidates for cancer treatment owing to their unique structural properties. In this study, a biocompatible delivery platform is developed by noncovalently incorporating cobalt metallacarborane (CoSAN) into hyaluronic acid (HA) functionalized with lysine (Lys). HA-Lys 2 enables the electrostatic interaction of CoSAN while retaining its cytotoxic activity, as confirmed by cellular assays using MDA-MB-231 triple-negative breast cancer cells. Elemental mapping via energy-dispersive X-ray spectroscopy (EDX) confirms the successful and homogeneous incorporation of CoSAN to lead HA-Lys-CoSAN 3, and the composite is further characterized using diffusion-ordered nuclear magnetic resonance (NMR) spectroscopy (DOSY). Stimulated Raman scattering (SRS) microscopy data demonstrate comparable cellular uptake in MDA-MB-231 cells of free and HA-loaded CoSAN. Additionally, release studies under physiologically relevant conditions show a sustained release profile over 24 h with pH dependency to mimic normal and tumor microenvironments. The present study describes a viable method for integrating metallacarboranes into a polymeric drug delivery system without compromising their anticancer properties, thereby advancing their potential for future therapeutic use.

Indexed as

Antineoplastic AgentsBoranesCobaltDrug CarriersDrug Delivery SystemsHydrogelsTriple Negative Breast NeoplasmsCell Line, TumorCell ProliferationCell SurvivalFemaleHumansHyaluronic AcidAntineoplastic AgentsBoranesCobaltDrug CarriersHyaluronic AcidHydrogelscobalt–bis(dicarbollide)hyaluronic acidmetallacarboranestargeted delivery systemstriple‐negative breast cancer

Identifiers

PMID41055887
PMCPMC12596922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.